Stress Disorders, Post-Traumatic
Conditions
Keywords
PTSD
Brief summary
This study will test the efficacy of the Freespira Breathing System in adults with post traumatic stress disorder (PTSD).
Detailed description
The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device , and has been employed in breathing biofeedback in adults with panic disorder (PD). The FBS has received FDA clearance for the treatment of PD adults and is currently commercially available. This study is a prospective, single arm, un-blinded investigation of the Freespira Breathing System in the PTSD population.
Interventions
Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
Sponsors
VA Palo Alto Health Care System
Palo Alto Health Sciences, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Note: Office visits required. Patients must live locally in San Francisco/Silicon Valley Bay Area to participate. Patients with a primary diagnosis of PTSD * Additional DSM-V disorders are acceptable and will be documented. * Subjects over 18 years of age * Subjects with a Clinician's Global Impression (CGI-S) score of ≥ 4 * Subjects with a CAPS-5 score of ≥ 30 * If on psychotropic medication(s), on a stable dose during the course of treatment * This can include benzodiazepine use that is prescribed on an as needed basis. • If on psychotropic medication(s), patient agreement to maintain their current stable dose from point of study entry until the 2-month post-treatment assessment.
Exclusion criteria
* Subject is pregnant. * Current enrollment in another device or drug study. * Enrollment in another drug or device study that is not at least 30 days past the final follow-up visit. * Currently undergoing cognitive behavioral therapy, or equivalent that is focused addressing PTSD including any evidenced based therapy that focuses on PTSD, including cognitive processing therapy, EMDR, prolonged exposure therapy, Virtual reality therapy, during trial and 2 month follow up. Cognitive therapy must be discontinued 1 month prior to enrolling in this study. * Severe suicidality, in the judgment of the interviewer and taking the CHART assessment into account * Psychotic disorder diagnosis, including schizophrenia and schizoaffective disorder * Presence of uncontrolled bipolar disorder as described below - * The subject has experienced a manic episode in the past 6 months and is not considered under control by reviewer * Bipolar disorder is considered the primary diagnosis for the subject, in the interviewer's opinion. * No Alcohol, drug use disorder that requires medical treatment . If stable under medical supervision treatment for drug/alcohol use, then OK * Cardiovascular or pulmonary disease, such as COPD. * Score of ≥ 10 on the COPD assessment * EtCO2 of ≥ 48 mmHg at first treatment visit * Epilepsy or seizures * Inability to understand or comply with study procedures. * The investigator feels that for any reason the subject is not eligible to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary outcome of this study will be quantitative improvements using the Clinician Administered PTSD Scale (CAPS - 5). | 2 month and 6 months post treatment | Using this scale, Response is defined as a reduction of 6 or more points. Remission is defined as Response plus no longer meeting clinical symptom criteria and having a severity score \< 25. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Patient Health Questionnaire (PHQ-9) Score | 2 month and 6 months post treatment | Change in condition (score) as recorded from baseline |
| Change in 36-Item Short Form Survey (SF-36) Score | 2 month and 6 months post treatment | Change in condition (score) as recorded from baseline |
| Change in Clinical Global Impression (CGC-S) Score | 2 month and 6 months post treatment | Change in condition (score) as recorded from baseline |
| Change in Panic Disorder and Severity Scale (PDSS) Score | 2 month and 6 months post treatment | Proportion achieving a clinically significant 40% decrease, proportion achieving a remission score \<= 5. |
| Proportion achieving Remission by CAPS-5 Score | 2 month and 6 months post treatment | Remission is defined as 'Response' plus no longer meeting clinical symptom criteria and having a severity score of \<25. |
Countries
United States
Outcome results
None listed